IL268813A - Mr1 restricted t cell receptors for cancer immunotherapy - Google Patents

Mr1 restricted t cell receptors for cancer immunotherapy

Info

Publication number
IL268813A
IL268813A IL26881319A IL26881319A IL268813A IL 268813 A IL268813 A IL 268813A IL 26881319 A IL26881319 A IL 26881319A IL 26881319 A IL26881319 A IL 26881319A IL 268813 A IL268813 A IL 268813A
Authority
IL
Israel
Prior art keywords
recognition
cell receptors
cancer immunotherapy
receptors specific
specific
Prior art date
Application number
IL26881319A
Other languages
English (en)
Hebrew (he)
Inventor
De Libero Gennaro
Lepore Marco
Mori Lucia
Original Assignee
Univ Basel
De Libero Gennaro
Lepore Marco
Mori Lucia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel, De Libero Gennaro, Lepore Marco, Mori Lucia filed Critical Univ Basel
Publication of IL268813A publication Critical patent/IL268813A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL26881319A 2017-03-07 2019-08-21 Mr1 restricted t cell receptors for cancer immunotherapy IL268813A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17159754 2017-03-07
EP17179309 2017-07-03
PCT/EP2018/055620 WO2018162563A1 (en) 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL268813A true IL268813A (en) 2019-10-31

Family

ID=61563412

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26881319A IL268813A (en) 2017-03-07 2019-08-21 Mr1 restricted t cell receptors for cancer immunotherapy

Country Status (9)

Country Link
EP (2) EP3592839B1 (enExample)
JP (2) JP7233103B2 (enExample)
KR (1) KR20190126332A (enExample)
CN (1) CN110462024B (enExample)
AU (1) AU2018231405B2 (enExample)
CA (1) CA3054758A1 (enExample)
IL (1) IL268813A (enExample)
WO (1) WO2018162563A1 (enExample)
ZA (1) ZA201905579B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
AU2018268087B2 (en) 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
JP7469807B2 (ja) * 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
BR112021003996A2 (pt) * 2018-09-12 2021-05-25 Universität Basel receptores de célula t restritos à mr1 para imunoterapia contra o câncer
SG11202105975SA (en) * 2018-12-06 2021-07-29 Guangdong Tcrcure Biopharma Technology Co Ltd Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119587561B (zh) * 2024-12-09 2025-11-28 新乡医学院 THP在制备增强Vγ9Vδ2 T细胞抗肿瘤疗效的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US7829289B2 (en) * 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
JP6126804B2 (ja) * 2012-07-25 2017-05-10 国立大学法人富山大学 Ｔ細胞受容体のクローニング方法
US10000546B2 (en) * 2013-03-13 2018-06-19 Health Research, Inc. Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen
WO2015149130A1 (en) * 2014-04-01 2015-10-08 The University Of Queensland Immunological reagents and uses therefor

Also Published As

Publication number Publication date
WO2018162563A1 (en) 2018-09-13
CN110462024A (zh) 2019-11-15
EP4273233A3 (en) 2023-11-15
ZA201905579B (en) 2024-08-28
JP2020527036A (ja) 2020-09-03
KR20190126332A (ko) 2019-11-11
AU2018231405A1 (en) 2019-09-26
JP7515209B2 (ja) 2024-07-12
CN110462024B (zh) 2024-08-09
CA3054758A1 (en) 2018-09-13
JP2023058659A (ja) 2023-04-25
EP3592839C0 (en) 2023-07-05
EP3592839A1 (en) 2020-01-15
AU2018231405B2 (en) 2024-02-08
EP4273233A2 (en) 2023-11-08
EP3592839B1 (en) 2023-07-05
JP7233103B2 (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
IL268813A (en) Mr1 restricted t cell receptors for cancer immunotherapy
IL282080A (en) Combinatorial cancer immunotherapy
IL271435A (en) T cell receptors
IL269810A (en) Combinatorial cancer immunotherapy
IL262128A (en) T cell receptors
IL262124A (en) T cell receptors
IL262146A (en) T cell receptors
EP3624810A4 (en) NANO-ACTIVATED IMMUNOTHERAPY FOR CANCER DISEASES
IL262144A (en) t cell receptors
IL264425B1 (en) t cell receptors against kras-g20
HUE059484T2 (hu) Az NY-ESO-1 tumorantigén - HLA-A
IL252937A0 (en) Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
DK3126390T3 (da) Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
DK3448882T3 (da) Anti-kk-lc-1-t-cellereceptorer
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3453406T3 (da) ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
EP3198010A4 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
IL280375A (en) Mr1 restricted t cell receptors for cancer immunotherapy
EP3597766A4 (en) NEW BIOMARKER FOR ANTI-CANCER IMMUNOTHERAPY
LT3433270T (lt) T ląstelių receptoriai
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
EP4025204A4 (en) Cancer immunotherapy
LT3317300T (lt) Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai
IL246540A0 (en) Freezeald receptor antibodies for cancer treatment
EP3679373A4 (en) IMPROVED IMMUNOTHERAPY